This meeting is for UK Oncology Healthcare Professionals only.
The meeting will run strictly in accordance with the ABPI Code of Practice. The varying sponsorships packages are primarily for the purchase of promotional virtual exhibition space.
CCA-UK Workshop (ALL HCPs WELCOME) Read more |
||||||
ACP AGM (MEMBERS ONLY) | ||||||
BOPA (INVITATION ONLY) | ||||||
NOTCH AGM (ALL HCPs WELCOME) | ||||||
UKONS MDT Reform Strategy into Practice (ALL HCPs WELCOME) | ||||||
UKOMiC Committee Meeting (MEMBERS ONLY) | ||||||
Merck/Pfizer IO-TKI Symposium (ALL HCPs WELCOME) BAVENCIO® (avelumab) + axitinib for advanced RCC CHAIR: Dr Sarah Rudman, Guy’s and St. Thomas’ NHS Foundation Trust London Dr Richard Griffiths, The Clatterbridge Cancer Centre Wirral Dr Robert Stevenson, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust Birmingham *Details of the programme attached with prescribing information & adverse event reporting included. This promotional meeting is organised and funded by Merck Serono Ltd on behalf of the Merck-Pfizer alliance and may include reference to Merck and Pfizer medicines relevant to the agenda topics. RCC, renal cell carcinoma. CDF, Cancer Drugs Fund. The UK Oncology Forum Faculty have had no influence or input into the programme or speaker choices CME is not awarded for commercial symposia BCTRCG (ALL HCPs WELCOME) |
- BCTRCG: Introduction and update on progress - PEAR: Current UK Practice for the Management of Pregnancy-Associated Breast Cancer - ALTRA: A national retrospective Audit on Long term TRAstuzumab use in metastatic breast cancer - PRIMROSE: A national prospective observational study in breast cancer patients with central nervous system involvement in the UK - Q&A/Open discussion *PLATINUM SPONSOR - Novartis BREAST Symposium (ALL HCPs WELCOME) | CHAIR: Prof Samreen Ahmed, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust - Opening and introduction (Prof Samreen Ahmed) - PIK3CA mutation and the importance of testing (Dr Philippe Taniere) - Piqray + fulvestrant: Learnings from SOLAR-1 (Prof Andrew Wardley) - Safety and how to manage your patients taking Piqray + fulvestrant (Prof Samreen Ahmed) - Live Q&A session and close (All) CME is not awarded for commercial symposia Exhibition & Charity Corner (PLEASE VISIT THE VIRTUAL STANDS) |
Welcome & Introduction, Professor Ruth Plummer |
Keynote 1 – Professor Gillian Griffiths, Cambridge
|
Exhibition & Charity Corner |
|
*Bayer Symposium (ALL HCPs welcome) ’Precision oncology and NTRK inhibitors – the histology independent approach to finding and treating patients?’ FACULTY Dr Alastair Greystoke (Chair), Newcastle University Dr Adam Dangoor, University Hospitals Bristol NHS Foundation Trust Dr Debashis Sarker Guy’s and St Thomas’ NHS Foundation Trust Welcome, introduction and agenda (Dr Alastair Greystoke) - The evolution of biomarkers, targeted therapy and tumour agnostic therapy (Dr Alastair Greystoke) - NTRK inhibitors (Dr Adam Dangoor) - Case studies of NTRK inhibitors (Dr Adam Dangoor) - NTRK gene fusions in the UK; who when and why to test (Dr Debashis Sarker) - Faculty Q&A and meeting close (All, Dr Alastair Greystoke) CME is not awarded for commercial symposia |
Exhibition & Charity Corner |
Clinical Streams – please click on the link below for the programme of preferred clinical sessions. You must view at least two clinical streams to qualify for your CME certificate and the keynote speakers. You are welcome to view all of the clinical sessions. CME points will not be awarded for commercial symposia. |
Exhibition & Charity Corner |
Introduction to Keynote 2 Speaker, Professor KT Patel Oxford University |
Exhibition & Charity Corner |
*GSK Gynae Symposium (ALL HCPs welcome) ’ Stepping through the patient journey: MDT approach to patient care in relapsed platinum sensitive ovarian cancer ’ Faculty: Chair: Marcia Hall, Helen Manderville, Jane Borley’ CME is not awarded for commercial symposia |
*AstraZeneca Symposium (ALL HCPs welcome) The evolving landscape in advanced NSCLC This symposium will explore evolving options for the treatment and management of stage III and stage IV non-small cell lung cancer (NSCLC) patients. A key topic to be addressed during this interactive session will be prehabilitation to optimise patient fitness prior to challenging treatment regimes, with best practice examples and practical guidance on how measures can be implemented across UK centres. The symposium will also feature the latest data updates from the PACIFIC and FLAURA clinical trials, with discussions around how these may impact UK clinical practice for these heterogenous groups of patients. CME is not awarded for commercial symposia |
*Pierre Fabre CRC Symposium (ALL HCPs welcome) A breakthrough in overall survival in BRAFV600E metastatic colorectal cancer patients ~ Welcome, introduction and session objectives (Professor Daniel Hochhauser) ~ The importance of resistance pathways within the MAPK Pathway (Professor Daniel Hochhauser) ~ What is the unmet need in BRAFV600E mutant metastatic colorectal cancer? (Professor Julien Taieb) ~ BEACON CRC data presentation (Professor Julien Taieb) ~ Speaker discussion (Professor Daniel Hochhauser and Julien Taieb) ~ Q&A and meeting close (Speakers and Audience) CME is not awarded for commercial symposia |
UK Cancer/Covid state of the nation grand discussion Chair Professor Andrew Wardley |
Athena Meetings and Events is a medical events agency and secretariat, that support global cancer meetings, cancer organisations and the pharmaceutical sector to deliver seamless, high quality educational meetings. Athena are proud of their esteemed reputation within the medical meetings space and with the cancer healthcare professionals that they work with closely, across the globe.
Athena Meetings & Events provides full secretariat support to the UK Oncology Forum annual meeting.
Over 20 Years of consistently delivering excellence in client service.
Athena Meetings & Events, The Science Park Building 23, Room 23S55, Mereside, Alderley Park, Alderley Edge, Cheshire, SK10 4TG
Synopsis : TBC
Chair: Mr Zaed Hamady, Vice President BASO~ACS
‘Welcome & introduction’
Professor Jayant Vaidya, Professor of Surgery and Oncology, University
College London
‘TARGIT-IORT for breast cancer’
Mr Myrddin (Merv) Rees, Consultant General & Hepatobiliary Surgeon
Basingstoke & North Hampshire Hospital
‘Debulking surgery for colorectal liver metastasis
‘
Professor Alex Mirnezami, Professor of Surgical Oncology & Consultant
Colorectal Surgeon, Southampton General Hospital
‘IORT in Gastro Intestinal Surgery’
Mr Zaed Hamady, Consultant General & Hepatobiliary Surgeon Southampton
University Hospital
‘Cancer Surgery and Covid-19’
Expert Panel
‘Discussion Session on ‘surgical input at MDMs’’
Mr Zaed Hamady, Vice President BASO~ACS
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis :
Welcome to our new format breast cancer sessions in UK Oncology Forum 2020. With have an exciting agenda this year in a live digital format with interactive discussions. We will be looking at all that is new in breast cancer in the last 12 months, particularly areas that may change our understanding and practice. Many women live with secondary breast for years- is it time we took a different perspective on this diagnosis reflecting outcomes more. We also take a surgical perspective to secondary disease and explore the role of local surgical treatments and benefits for people. Of course no session is complete without looking at the effects of COVID for people with breast cancer in the last months, both medically and socially. We all look forward to seeing all on our screens!
Dr Marina Parton & Dr Mark Verrill
‘Welcome & Introduction’
Dr Olga Oikonomidou
’What’s new in breast cancer in the past year’
Mr Stuart McIntosh
‘Surgery in MBC’
Professor Andrew Wardley
‘Breast Cancer as a Chronic Disease’
Ms Karen Verrill
‘Cancer doesn’t stop because of Coronavirus’
Expert Panel
‘Discussion’
Dr Marina Parton & Dr Mark Verrill
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis : TBC
Dr Vicky Coyle
‘Welcome & Introduction’
Dr Naureen Starling
‘
ctDNA guided treatment in colorectal cancer’
Dr Paul Ross
Assessment and management of older patients with CRC
Dr Jenny Seligmann
‘ASCO & ESMO CRC highlights and insights
‘
Expert Panel
‘Discussion’
Dr Vicky Coyle
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis : TBC
Dr Rebecca Kristeleit, Chair
‘Welcome & Introduction’
Professor James Brenton
'Genetic testing, genomics and HRD in ovarian cancer and possible extension to endometrial cancer'
Dr Yvette Drew
‘Updates on the systemic management of advanced Endometrial cancer’
Dr Dennis Hadjiyiannakis
‘Hot topics in current gynae radiotherapy’
Dr Carien Creutzberg
‘GCIC endometrial cancer translational research’
Expert Panel
‘Discussion’
Dr Rebecca Kristeleit, Chair
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis : TBC
Professor Terry Jones
‘Welcome & Introduction’
Dr David Thomson
'The future role of proton therapy in the management of head and neck cancer'
Professor Christian Simon
'New Frontiers in H&N Cancer Treatment a surgical perspective'
Professor Mererid Evans
'De-intensification treatment strategies for HPV-positive oropharynx cancer'
Dr Martin Forster
'H&N highlights from ASCO & ESMO'
Expert Panel
‘Discussion’
Professor Terry Jones, Chair
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis : TBC
Professor Derek O’Reilly
‘Welcome & Introduction’
Dr Ganash Radhakrishna
‘Irradiating the liver: adding insult to injury?’
Professor John Bridgewater
'New EPOC - trials and tribulations'
Dr David Chang
‘Precision-Panc platform; precision medicine in pancreatic cancer
and integrating chemotherapy, rad and surgery in clinical trials
and in practice.’
Professor Eithne Costello
‘UK-EDI study
’
Expert Panel
‘Discussion’
Professor Derek O’Reilly
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis : TBC
Dr Fiona McDonald
‘Welcome & Introduction’
Dr Riyaz Shah
‘What is new in the mutation positive disease population?
‘
Tom Newsom-Davis
‘How do we treat patients with no actionable mutations?
‘
Professor Matthias Guckenberger, Zurich
‘What is the role of radiotherapy in metastatic lung cancer?
‘
Professor Samreen Ahmed
‘How do we treat patients with small cell lung cancer & does
radiotherapy still have a role?
‘
Expert Panel
‘Discussion’
Dr Fiona McDonald
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis :
This tumour site specific session will update the audience on the recent advances in treatment of melanoma with a multi-disciplinary team of speakers covering all aspects of management. Updates from the two major international cancer research conferences will provide the latest clinical trial data, in addition to presentations on cutting edge science in the clinic. The interactive session will allow the audience to discuss and debate changes in management that have been needed during the pandemic, and explore best practice in this area.
Professor Ruth Plummer
‘Welcome & Introduction’
Dr Joe Sacco
'Intralesional therapy- harnessing the abscopal effect'
Mr Howard Peach
'Covid pandemic altered the management of patients with melanoma'
Dr Sophie Papa
'Updates from ASCO & Melanoma'
Dr Christian Blank
‘Neoadjuvant treatment of stage III melanoma’
Expert Panel
‘Discussion’
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis :
‘The radiotherapy revolution?
Radiotherapy - boring, archaic and toxic or exciting, innovative
and crucial to cancer treatment? Did you know that 50% of patients
cured of cancer have radiotherapy? Come and find out how
immunotherapy, protons, ablation of metastases and personalised
care for an ageing population is revolutionising radiotherapy in
the UK’
Dr Alison Tree
‘Welcome & Introduction’
Professor Neil Burnet
‘Protons: more hype than substance?’
Dr Anthea Cree
‘Radiotherapy for the older cancer patient’
Dr Nora Sundahl
‘The abscopal effect – rarer than unicorns?’
Dr David Palma
‘Stereotactic radiation for metastases: taking it from oligomets to ARREST’
Expert Panel
‘Discussion’
Dr Alison Tree
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis :
‘
Local (primary and mets) and potentially combination treatment
strategies in systemic disease: Who? When ? How ? and what next?’
Dr Nick Van As, Chair
‘Welcome & Introduction’
Mr P. Sooriakumaran
‘Surgery’
Dr Aidan Cole (Day 1) & Professor Joe O'Sullivan (Day 2)
‘Bone health agents in men with metastatic prostate cancer
‘
Dr Alison Reid
'Systemic therapies’
Dr Barbara Jereczek-Fossa
'Local radiotherapy in systemic disease: a new paradigm?’
Expert Panel
‘Discussion’
Dr Nick Van As, Chair
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis: Systemic treatment options in renal cancer have expanded dramatically in the past decade with the evolution of effective immunomodulating agents which have transformed the prognosis for patients with metastatic disease. In this session we will provide an overview of the agents now available and consider the optimal sequencing where multiple agents are available.
Bladder preservation is increasing in prominence when considering curative treatment of muscle invasive bladder cancer using trimodality therapy incorporating radiotherapy and a radiosensitiser. Personalised optimisation of treatment is the ultimate goal of any cancer therapy. Identification of predictive biomarkers is key to this and is the subject of the final component of this session.
Objectives:
Gain knowledge of the available systemic treatments for renal cancer
Understand the rationale for different sequencing of systemic therapies
Discuss the role of biomarkers in personalising management of muscle invasive bladder cancer
Prof Peter Hoskin (R) / Professor Ananya Choudhury (B)
‘Welcome & Introduction’
Dr Simon Crabb
'Newer classifications around Bladder/Kidney treatment'
Mr Rajesh Nair
‘Urology Upper tract surgery’
Dr Manon Pillai
‘Kidney sequencing’
Prof Ananya Choudhury
'A personalised approach to bladder radiotherapy"
Expert Panel
‘Discussion’
Prof Peter Hoskin (R) / Professor Ananya Choudhury (B)
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis :
Sexual Health and Cancer
‘To raise awareness of the challenges and issues, patients with
cancer experience in relation to sexual health, considering both
the physical and emotionally effects in context.’
Kay Bell
‘Welcome & Introduction’
Dr Jane Frankland
‘Sexual well-being among people living with and beyond cancer: findings from the Macmillan CREW and HORIZONS cohort studies’
Clare Johnson
‘Experiences of breast cancer treatment on body image’
Liz O’Riordan
‘Whose job is it to talk about sex anyway?’
Dr Alison May Berner
‘Providing personalised care for gender diverse patients
’
Expert Panel
‘Discussion’
Kay Bell
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis :
This session will provide a comprehensive update on management of brain metastases, including available treatment options and factors which influence patient selection and MDT decision making. State of the art neurosurgery, stereotactic radiosurgery (SRS) and systemic therapy will be described. Choice and sequencing of these treatments will be illustrated and discussed via a series of case histories, deliberately selected to highlight controversies in this field.
The session will also include an update on systemic and novel therapies for gliomas, including the status of personalised medicine, immunotherapy and tumour-agnostic agents in primary brain tumours. The session aims to whet the appetite of non-neuro-oncologists by highlighting the challenges and opportunities in this field.
09:00hrs ~ 09.10hrs - Welcome & introduction (Dr Catherine McBain)
09:10hrs ~ 09.35hrs - Modern neurosurgical thinking and techniques in brain tumours (Mr Pietro D-Urso)
09:35hrs ~ 10.00hrs - Systemic therapies for gliomas: Challenges and opportunities (Dr Fiona Collinson)
10:00hrs ~ 10:15hrs - Radiotherapy and SRS for brain metastases (Dr Paul Sanghera)
10:15hrs ~ 10:30hrs - Systemic therapy for brain metastases (Dr Gary Doherty)
10:30hrs ~ 11:25hrs - Multidisciplinary management of brain metastases: case histories with discussion and questions
11:25hrs ~ 11:30hrs - Conclusion and close (Dr Catherine McBain)
Synopsis : ‘
Personalised care and cancer- it’s everyone’s business’
Dr Anthony Cunliffe
‘Welcome & Introduction’
Ensuring that people living with cancer receive personalised care is
everyone’s business, with contacts from the point of diagnosis, through
prehabilitation, making treatment decisions and going through
treatment, acutely unwell episodes, good quality cancer care review
conversations, needs assessments, gaining support from social
prescribers and courageous end of life care conversations.
In this workshop, we’ll explore how we can build on the strengths of the multiple different professionals involved in delivering care to people following a cancer diagnosis by focusing on the unique touchpoints and opportunities they have. Through the use of case studies, we’ll generate an interactive conversation based around the key times of need experienced by cancer patients to draw out what each individual can bring to achieving personalised care.
Subjects to be covered:-
Delivering personalised care at:
• The point of diagnosis
• Prehabilitation
• Treatment including the acutely unwell patient
• Cancer Care Reviews
• Communication across pathways including the use of the electronic Holistic Needs Assessment in the community and utilisation of Treatment Summaries
• Social Prescribing
• Courageous conversations at the end of life
Dr Anthony Cunliffe
Dr Ashling Lillis
Sophia Nicola
June Davis
Dr Anthony Cunliffe
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
Synopsis :
In this interactive session we will discuss state of the art multidisciplinary management of gastric and oesophageal cancer . Talks will cover recent advances in radiotherapy, surgery and systemic therapy and provide trial and clinical research updates including those recently presented at ASCO 2020 and ESMO 2020 focussing on the impact trial results have for clinical practice .
Dr Janet Graham/Professor Russell Petty
‘Welcome & Introduction’
Professor Maria Hawkins
‘Advances in radiotherapy and what’s on the horizon for OG cancer’
Prof Tim Underwood
‘Minimally invasive surgery and the role of robotic surgery
‘
Professor Russell Petty
‘Precision medicine in biology OG’
Dr Naureen Starling
‘The role of IO in OG cancers and where the field currently is
(ASCO Updates)’
Professor Saleh Al-Batran (Germany)
‘Optimal (neo) adjuvant treatment’
Expert Panel
‘Discussion’
Dr Janet Graham/Professor Russell Petty
‘Q&A, Chairman’s thoughts, wrap up and evaluation’
UKOMiC Workshop UK Oncology Forum: Friday 25th September 09.00-11.30.
Welcome to the UKOMiC/UK Oncology Forum ‘Oral Care in Cancer Workshop’. The workshop will be led by dental, oncologist and nursing experts from the UK and the European Oral Care in Cancer Expert Working Groups. The speakers and workshop we will present and explore - advances in cancer treatments and the impact on the oral/dental cavity, the role of dentistry in the head and neck setting, the importance of multi-professional working, addressing graft versus host disease and ways to improve working between the hospital and community settings.
Dr Charles Kelly (Chair) - Welcome & Introduction
09.00hrs ~ 09:20hrs - Dr Clare Morgan
Dentistry in the head and neck cancer setting
09:20hrs ~ 09:25hrs - Chair Q&A
09:25hrs ~ 09:45hrs - Dr Barry Quinn
New advances and oral care
09:45hrs ~ 09:50hrs Chair - Q&A
09.50hrs ~ 10:00hrs -- Break
10:00hrs ~ 10:20hrs - Dr Marinka Mravak-Stipetic
A team approach and managing graft versus host disease
10:20hrs ~ 10.25hrs - Chair - Q&A
10.25hrs ~ 10.45hrs - Ms Joss Harding
Working with community services
10.45hrs ~ 10:50hrs Chair - Q&A
10.50hrs ~ 11.20hrs - Expert Panel Interactive discussion
11:20hrs ~ 11.30hrs Chair - Thoughts, evaluation and summary